@article{0bdbbbae25ca4c958cd020dfbd51c591,
title = "Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology",
abstract = "Introduction: Coronavirus disease 2019 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which enters host cells through the cell surface proteins ACE2 and TMPRSS2. Methods: Using a variety of normal and malignant models and tissues from the aerodigestive and respiratory tracts, we investigated the expression and regulation of ACE2 and TMPRSS2. Results: We find that ACE2 expression is restricted to a select population of epithelial cells. Notably, infection with SARS-CoV-2 in cancer cell lines, bronchial organoids, and patient nasal epithelium induces metabolic and transcriptional changes consistent with epithelial-to-mesenchymal transition (EMT), including up-regulation of ZEB1 and AXL, resulting in an increased EMT score. In addition, a transcriptional loss of genes associated with tight junction function occurs with SARS-CoV-2 infection. The SARS-CoV-2 receptor, ACE2, is repressed by EMT through the transforming growth factor-β, ZEB1 overexpression, and onset of EGFR tyrosine kinase inhibitor resistance. This suggests a novel model of SARS-CoV-2 pathogenesis in which infected cells shift toward an increasingly mesenchymal state, associated with a loss of tight junction components with acute respiratory distress syndrome-protective effects. AXL inhibition and ZEB1 reduction, as with bemcentinib, offer a potential strategy to reverse this effect. Conclusions: These observations highlight the use of aerodigestive and, especially, lung cancer model systems in exploring the pathogenesis of SARS-CoV-2 and other respiratory viruses and offer important insights into the potential mechanisms underlying the morbidity and mortality of coronavirus disease 2019 in healthy patients and patients with cancer alike.",
keywords = "ACE2, AXL, EMT, NSCLC, SARS-CoV-2, ZEB1",
author = "Stewart, {C. Allison} and Gay, {Carl M.} and Kavya Ramkumar and Cargill, {Kasey R.} and Cardnell, {Robert J.} and Nilsson, {Monique B.} and Simon Heeke and Park, {Elizabeth M.} and Kundu, {Samrat T.} and Lixia Diao and Qi Wang and Li Shen and Yuanxin Xi and Bingnan Zhang and {Della Corte}, {Carminia Maria} and Youhong Fan and Kiran Kundu and Boning Gao and Kimberley Avila and Pickering, {Curtis R.} and Johnson, {Faye M.} and Jianjun Zhang and Humam Kadara and Minna, {John D.} and Gibbons, {Don L.} and Jing Wang and Heymach, {John V.} and Byers, {Lauren Averett}",
note = "Funding Information: We wish to acknowledge the patients affected by the coronavirus disease 2019 pandemic, along with their loved ones, the first responders, health care staff, and essential workers who worked tirelessly and selflessly during this devastating period. We thank C.E.S. for graphical elements and David M. Aten for assistance with medical illustrations. We thank P.M.G., M.P.B., W.A.B., G.D.S., P.W.S., R.A.S., R.R.S., R.A.D., B.A.D., V.J.M.C., S.C., S.C., J.P., S.I.1., S.I.2., and C.J.C. for intellectual support provided during quarantine. The work was supported by the National Institutes of Health (NIH)/National Cancer of Institute (NCI) R50-CA243698 (Dr. Stewart), NIH/NCI R01-CA207295 (Dr. Byers), NIH/NCI U01-CA213273 (Drs. Byers, Heymach), CCSG P30-CA01667 (Dr. Byers), University of Texas SPORE in Lung Cancer P5-CA070907 (Drs. Byers, Gibbons, Heymach, Gay, Wang, Ramkumar, Cargill), NIH/NCI R37CA214609 (Dr. Gibbons), the Department of Defense (LC170171; Byers), Khalifa Bin Zayed Al Nahyan Foundation (Dr. Gay), CPRIT Research Training Program RP170067 (Dr. Park), The International Association for the Study of Lung Cancer (Dr. Cargill), The University of Texas MD Anderson Cancer Center-Oropharynx Cancer Program generously supported by Mr. and Mrs. Charles W. Stiefel (Dr. Johnson), through generous philanthropic contributions to The University of Texas MD Anderson Lung Cancer Moon Shot Program, The Jane Ford Petrin Fund, The Andrew Sabin Family Fellowship, and The Rexanna Foundation for Fighting Lung Cancer. Funding Information: Disclosure: Dr. Byers reports serving on advisory committees for AstraZeneca, AbbVie, GenMab, BergenBio, Pharma Mar SA, Sierra Oncology, Merck, Bristol-Myers Squibb, Genentech, and Pfizer and receiving research support from AbbVie, AstraZeneca, GenMab, Sierra Oncology, and Tolero Pharmaceuticals. Dr. Heymach reports serving on advisory committees for AstraZeneca, Boehringer Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Guardant Health, Foundation Medicine, Hengrui Therapeutics, Eli Lilly, Novartis, Spectrum, Sanofi, Takeda, Mirati Therapeutics, Bristol-Myers Squibb, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, EMD Serono, Pneuma Respiratory, Kairos Venture Investments, Roche, and Leads Biolabs; receiving research support from AstraZeneca, Bayer, GlaxoSmithKline, and Spectrum; having patents PCT/US2019/024353-UTFC.P1354AE, 62/793,565/PCT/US2020/013889, 62/967,282, 62/895,322-17/011,519, 62/929,840/PCT/US2020/058548, and 62/967,275/UTSC.P1499US.P1; and receiving royalties and licensing fees from Spectrum. Dr. Gibbons reports serving on scientific advisory committees for AstraZeneca, GlaxoSmithKline, Sanofi, and Janssen and receiving research support from Janssen, Takeda, Ribon Therapeutics, Astellas, and AstraZeneca. Dr. Johnson reports receiving donor research funds. Dr. Gay reports receiving research funding from AstraZeneca. Dr. Minna reports receiving royalties and licensing from distribution of cell lines from the National Institutes of Health and The University of Texas Southwestern. Dr. Nilsson reports receiving royalties and licensing fees from Spectrum. Zhang reports receiving grants from Merck and Johnson and Johnson and personal fees from Bristol-Myers Squibb, AZ, GenePlus, and Innovent outside of the submitted work. Dr. Kadara reports receiving grant from Johnson and Johnson. The remaining authors declare no conflict of interest.We wish to acknowledge the patients affected by the coronavirus disease 2019 pandemic, along with their loved ones, the first responders, health care staff, and essential workers who worked tirelessly and selflessly during this devastating period. We thank C.E.S. for graphical elements and David M. Aten for assistance with medical illustrations. We thank P.M.G. M.P.B. W.A.B. G.D.S. P.W.S. R.A.S. R.R.S. R.A.D. B.A.D. V.J.M.C. S.C. S.C. J.P. S.I.1. S.I.2. and C.J.C. for intellectual support provided during quarantine. The work was supported by the National Institutes of Health (NIH)/National Cancer of Institute (NCI) R50-CA243698 (Dr. Stewart), NIH/NCI R01-CA207295 (Dr. Byers), NIH/NCI U01-CA213273 (Drs. Byers, Heymach), CCSG P30-CA01667 (Dr. Byers), University of Texas SPORE in Lung Cancer P5-CA070907 (Drs. Byers, Gibbons, Heymach, Gay, Wang, Ramkumar, Cargill), NIH/NCI R37CA214609 (Dr. Gibbons), the Department of Defense (LC170171; Byers), Khalifa Bin Zayed Al Nahyan Foundation (Dr. Gay), CPRIT Research Training Program RP170067 (Dr. Park), The International Association for the Study of Lung Cancer (Dr. Cargill), The University of Texas MD Anderson Cancer Center-Oropharynx Cancer Program generously supported by Mr. and Mrs. Charles W. Stiefel (Dr. Johnson), through generous philanthropic contributions to The University of Texas MD Anderson Lung Cancer Moon Shot Program, The Jane Ford Petrin Fund, The Andrew Sabin Family Fellowship, and The Rexanna Foundation for Fighting Lung Cancer. Publisher Copyright: {\textcopyright} 2021 International Association for the Study of Lung Cancer",
year = "2021",
month = nov,
doi = "10.1016/j.jtho.2021.07.002",
language = "English (US)",
volume = "16",
pages = "1821--1839",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "11",
}